Real‐world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort

Autor: Cher Shiong Chuah, Ian D. Arnott, Nikolas Plevris, Gareth R. Jones, Wai Liam Lam, Rebecca Hall, Amy Tyler, S Siakavellas, Jayne Saunders, Philip Jenkinson, Claire Kane, Jennifer Veryan, Andrew Robertson, Graham Naismith, Gillian H Bain, Iona Campbell, L Potts, Christopher Kelly, Daniel R. Gaya, Craig Mowat, H. Jafferbhoy, James Fulforth, John Paul Seenan, Diarmid Ian Sutherland, Charlie W. Lees, David Watts, Jonathan Macdonald

Publikováno v: Journal of Gastroenterology and Hepatology. 36:2067-2075

BACKGROUND AND AIM Ustekinumab is a monoclonal antibody that targets interleukin-12/23. In Scotland, it was approved for the treatment of moderate to severe Crohn's disease in 2017. The objective of this study was to establish the real-world effectiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7eef0e05b51c3388fd468aec01e6e0d
https://doi.org/10.1111/jgh.15390

DOP72 Perianal Crohn’s Disease in the biologic era: A population-based cohort study

Autor: Charlie W. Lees, I. D. R. Arnott, Mathew Lyons, N Plevris, G R Jones, Angus Watson, S Siakavellas, P Jenkinson

Publikováno v: Journal of Crohn's and Colitis. 15:S105-S107

Background Peri-anal Crohn’s disease (pCD) significantly affects quality of life in patients with CD. The natural history of pCD in the era of biologic therapy is poorly understood. Perianal surgery includes examination under anaesthesia (EUA), dra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::64c4f84fd6ce3aad81ecc2303054a56a
https://doi.org/10.1093/ecco-jcc/jjab073.111

P579 Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease

Autor: L Derikx, N Plevris, S Su, B Gros, M Lyons, S Siakavellas, N Constantine-Cook, P Jenkinson, C O’Hare, L Merchant, C Noble, I Arnott, G Jones, C Lees

Publikováno v: Journal of Crohn's and Colitis. 16:i519-i520

Background The efficacy and safety of ustekinumab (UST) intravenous induction followed by 8- and 12- weekly maintenance was established in the UNITI controlled trial. These data report dose intensification for 12- to 8-weekly but not 4-weekly. The ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1893bbad4cecd9b8cff7f8244834878b
https://doi.org/10.1093/ecco-jcc/jjab232.705

Temporal Trends in Surgical Resection Rates and Biologic Prescribing in Crohn's Disease: A Population-based Cohort Study

Autor: David C. Wilson, Nikolas Plevris, Philip Jenkinson, Angus Watson, S Siakavellas, Charlie W. Lees, Mathew Lyons, G R Jones, I. D. R. Arnott

Publikováno v: Jenkinson, P W, Plevris, N, Siakavellas, S, Lyons, M, Arnott, I D, Wilson, D, Watson, A J M, Jones, G & Lees, C W 2020, ' Temporal Trends in Surgical Resection Rates and Biologic Prescribing in Crohn’s Disease : A Population-based Cohort Study ', Journal of Crohn's and Colitis, vol. 14, no. 9, pp. 1241-1247 . https://doi.org/10.1093/ecco-jcc/jjaa044

Background The use of biologic therapy for Crohn’s disease [CD] continues to evolve, however, the effect of this on the requirement for surgery remains unclear. We assessed changes in biologic prescription and surgery over time in a population-base

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dde0c82228aafa6645c9fe44c15fb26e
https://pubmed.ncbi.nlm.nih.gov/32840295

P154 Faecal calprotectin and patient reported disease control of IBD: results from the baseline dataset of the PREdiCCt study

Autor: G R Jones, L Williams, N Constantine-Cooke, K Covil, Laura Lucaciu, S Siakavellas, L Derr, L Murdoch, Lauranne A A P Derikx, Charlie W. Lees, Philip Jenkinson, Nikolas Plevris

Publikováno v: Journal of Crohn's and Colitis. 15:S233-S234

Background There is an established disconnect between intestinal inflammation and symptoms in patients with IBD. Faecal calprotectin (FCAL) is an excellent surrogate for mucosal healing and we have good data to support treat to target approaches base

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d994c7334d6484c8518ccdeb2a49ba22
https://doi.org/10.1093/ecco-jcc/jjab076.281